GABAergic system in action: Connection to gastrointestinal stress-related disorders

Current Pharmaceutical Design

Volumn 23, Issue 27, 2017, Pages 4003-4011

  Jembrek, Maja Jazvinšćak ^a,b   Auteri, Michelangelo ^c   Serio, Rosa ^c   Vlainić, Josipa ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b Croatian Academy of Medical Sciences Zagreb   (Croatia)

^c UNIVERSITY OF PALERMO   (Italy)

Author keywords

Benzodiazepines; GABAergic system; Gastrointestinal system; Stress; Stress related disorders; Therapy

Indexed keywords

2,6 DI TERT BUTYL 4 (3 HYDROXY 2,2 DIMETHYLPROPYL)PHENOL; 3 AMINO 2 (3 CARBOXYPROPYL) 6 (4 METHOXYPHENYL)PYRIDAZINIUM BROMIDE; 4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID C RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR; ANTALARMIN; BACLOFEN; BENZODIAZEPINE; BICUCULLINE; CORTICOTROPIN RELEASING FACTOR; GABAERGIC RECEPTOR AFFECTING AGENT; GLUTAMATE DECARBOXYLASE; BENZODIAZEPINE DERIVATIVE;

ANALGESIA; AUTOCRINE EFFECT; DIGESTIVE SYSTEM INFLAMMATION; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SYNTHESIS; GABAERGIC SYSTEM; GABAERGIC TRANSMISSION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HUMAN; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASE; INTESTINE CONTRACTION; INTESTINE FLORA; INTESTINE MUCOSA; IRRITABLE COLON; MENTAL STRESS; NOCICEPTION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STOMACH ACID SECRETION; STRESS; STRESS RELATED GASTROINTESTINAL DISORDER; TRANQUILIZING ACTIVITY; ANIMAL; COMPLICATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; BENZODIAZEPINES; GAMMA-AMINOBUTYRIC ACID; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; RECEPTORS, GABA; STRESS, PSYCHOLOGICAL;

EID: 85029828245     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612823666170209155753     Document Type: Review

References (143)

1. Furness JB. The organisation of the autonomic nervous system:peripheral connections. Auton Neurosci 2006; 130(1-2): 1-5.
2. Goyal RK, Hirano IH. The Enteric Nervous System. N Engl J Med 1996; 334: 1106-15.
3. Rescigno M. Don’t forget to have a “second brain”. Mucosal Immunol 2008; 1: 328-9.
4. Genton L, Kudsk KA. Interactions between the enteric nervous system and the immune system: role of neuropeptides and nutrition. Am J Surgery 2003; 186: 253-8.
5. Selye H. Syndrome produced by diverse nocuous agents. Nature 1936; 138: 32.
6. Szabo S, Tache Y, Somogyi A. The legacy of Hans Selye and the origins of stress research: a retrospective 75 years after his landmark brief “letter” to the editor of nature. Stress 2012; 15(5): 472-8.
7. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol 2005; 67: 259-84.
8. Habib KE, Gold PW, Chrousos GP. Neuroendocrinology of stress. Endocrinol Metab Clin North Am 2001; 30(3): 695-728
9. McEwen BS. Protection and damage from acute and chronic stress:allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Ann N Y Acad Sci 2004; 1032: 1-7.
10. Lupien SJ, McEwen BS, Gunnar MR, Heim C. Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nat Rev Neurosci 2009; 10(6): 434-45.
11. Ziegler DR, Herman JP. Neurocircuitry of stress integration: anatomical pathways regulating the hypothalamo-pituitaryadrenocortical axis of the rat. Integr Comp Biol 2002; 42(3): 541-51.
12. Stengel A, Tache Y. Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) 2010; 235(10): 1168-78.
13. Bunnett NW. The stressed gut: contributions of intestinal stress peptides to inflammation and motility. Proc Natl Acad Sci USA 2005; 102(21): 7409-10.
14. la Fleur SE, Wick EC, Idumalla PS, Grady EF, Bhargava A. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci USA 2005; 102(21): 7647-52.
15. Martinez V, Wang L, Million M, Rivier J, Tache Y. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 2004; 25(10): 1733-44.
16. Anton PM, Gay J, Mykoniatis A et al. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin Amediated intestinal inflammation. Proc Natl Acad Sci USA 2004; 101(22): 8503-8.
17. Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003; 10(1): 61-7.
18. Fadgyas-Stanculete M, Buga AM, Popa-Wagner A, Dumitrascu DL. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry 2014; 2(1): 4.
19. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut:pathophysiology, clinical consequences, diagnostic approach and treatment options. J Physiol Pharmacol 2011; 62(6): 591-9.
20. Mikocka-Walus A, Turnbull D, Moulding N, Wilson I, Andrews JM, Holtmann G. Psychological comorbidity and complexity of gastrointestinal symptoms in clinically diagnosed irritable bowel syndrome patients. J Gastroenterol Hepatol 2008; 23(7 Pt 1): 1137-43.
21. Margolis KG, Stevanovic K, Karamooz N, et al. Enteric neuronal density contributes to the severity of intestinal inflammation. Gastroenterology 2011; 141(2): 588-98, 598.e1-2.
22. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010; 7(3): 163-73.
23. Di Nardo G, Blandizzi C, Volta U, et al. Review article: molecular, pathological and therapeutic features of human enteric neuropathies. Aliment Pharmacol Ther 2008; 28(1): 25-42.
24. Krantis A. GABA in the mammalian enteric nervous system. News Physiol Sci 2000; 15: 284-90.
25. Rudolph U, Knoflach F. Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes. Nat Rev Drug Discov 2011; 10(9): 685-97.
26. Ferando I, Mody I. Interneuronal GABAA receptors inside and outside of synapses. Curr Opin Neurobiol 2014; 26: 57-63.
27. Bowery NG, Bettler B, Froestl W, et al. International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acid (B) receptors:structure and function. Pharmacol Rev 2002; 54(2): 247-64.
28. Olsen RW, Sieghart W. International union of pharmacology. LXX. Subtypes of gamma-aminobutyric acid (A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update Pharmacol Rev 2008; 60(3): 243-60.
29. Johnston GAR. Medicinal chemistry and molecular pharmacology of GABAC receptors. Curr Top Med Chem 2000; 2: 903-13.
30. Zhang D, Pan Z-H, Awobuluyi M, Lipton SA. Structure and function of GABAC receptors: a comparison of native versus recombinant receptors. Trends Pharmacol Sci 2001; 22: 121-32.
31. Miller PS, Smart TG. Binding, activation and modulation of Cysloop receptors. Trends Pharmacol Sci 2010; 31(4): 161-74.
32. Sigel E, Steinmann ME. Structure, function, and modulation of GABA(A) receptors. J Biol Chem 2012; 287(48): 40224-31.
33. Sieghart W, Fuchs K, Tretter V, et al. Structure and subunit composition of GABA receptors. Neurochem Int 1999; 34: 379-85.
34. Uusi-Oukari M, Korpi ER. Regulation of GABAA receptor subunit expression by pharmacological agents. Pharmacol Rev 2010; 62(1):97-135.
35. Hortnagl H, Tasan RO, Wieselthaler A, Kirchmair E, Sieghart W, Sperk G. Patterns of mRNA and protein expression for 12 GABAA receptor subunits in the mouse brain. Neuroscience 2013; 236: 345-72.
36. Laurie DJ, Seeburg PH, Wisden W. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. J Neurosci 1992; 12(3): 1063-76.
37. Wisden W, Laurie DJ, Monyer H, Seeburg PH. The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992; 12(3): 1040-62.
38. Johnston GAR. GABA(A) receptor channel pharmacology. Curr Pharm Des 2005; 11(15): 1867-85.
39. Fritschy JM, Panzanelli P. GABAA receptors and plasticity of inhibitory neurotransmission in the central nervous system. Eur J Neurosci 2014; 39(11): 1845-65
40. Jazvinšćak Jembrek M, Vlainić J, Šuran J. Zolpidem withdrawal induced uncoupling of GABAA receptors in vitro associated with altered GABAA receptor subunit mRNA expression. Acta Neurobiol Exp 2015; 75: 160-71.
41. Peričić D, Švob Štrac D, Jazvinšćak Jembrek M, Vlainić J. Allosteric uncoupling and up-regulation of benzodiazepine and GABA recognition sites following chronic diazepam treatment of HEK 293 cells stably transfected with α1β2γ2S subunits of GABAA receptors. Naunyn Schmiedebergs Arch Pharmacol 2007; 375: 177-87.
42. Jazvinšćak Jembrek M, Švob Štrac D, Vlainić J, Peričić D. The role of transcriptional and translational mechanisms in flumazenilinduced up-regulation of recombinant GABAA receptors. Neurosci Res 2008; 61: 234-41.
43. Jazvinšćak Jembrek M, Vlainić J. GABA receptors: pharmacological potential and pitfalls. Curr Pharm Design 2015; 21(34): 4943-59.
44. Bettler B, Tiao JY-H. Molecular diversity, trafficking and subcelullar localization of GABAB receptors. Pharmacol Ther 2006; 110:533-43.
45. Armijo JA, Shushtarian M, Valdizan EM, Cuadrado A, de las Cuevas I, Adin J. Ion channels and epilepsy. Curr Pharm Des 2005; 11(15): 1975-2003.
46. Shinozaki H, Ishida M. Excitatory amino acids: physiological and pharmacological probes for neuroscience research. Acta Neurobiol Exp (Wars) 1993; 53(1): 43-51.
47. Kulik A, Vida I, Lujan R, et al. Subcellular localization of metabotropic GABA(B) receptor subunits GABA(B1a/b) and GABA(B2) in the rat hippocampus. J Neurosci 2003; 23(35):11026-35.
48. Tao W, Higgs MH, Spain WJ, Ransom CB. Postsynaptic GABAB receptors enhance extrasynaptic GABAA receptor function in dentate gyrus granule cells. J Neurosci 2013; 33(9): 3738-43.
49. Kaupmann K, Malitschek B, Schuler V, et al. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 1998; 396(6712): 683-7.
50. Margeta-Mitrovic M, Jan YN, Jan LY. A trafficking checkpoint controls GABA(B) receptor heterodimerization. Neuron 2000; 27(1): 97-106.
51. Pin J-P, Kniazeff J, Binet V, et al. Activation mechanism of the heterodimeric GABAB receptor. Biochem Pharmacol 2004; 68:1565-72.
52. Malitschek B, Schweizer C, Keir M, et al. The N-terminal domain of γ-aminobutyric Acid(B) receptors is sufficient to specify agonist and antagonist binding. Mol Pharmacol 1999; 56(2): 448-54.
53. Nomura R, Suzuki Y, Kakizuka A, Jingami H. Direct detection of the interaction between recombinant soluble extracellular regions in the heterodimeric metabotropic γ-aminobutyric acid receptor. J Biol Chem 2008; 283(8): 4665-73.
54. Steiger JL, Bandyopadhyay S, Farb DH, Russek SJ. cAMP response element-binding protein, activating transcription factor-4, and upstream stimulatory factor differentially control hippocampal GABABR1a and GABABR1b subunit gene expression through alternative promoters. J Neurosci 2004; 24(27): 6115-26.
55. Geng Y, Bush M, Mosyak L, Wang F, Fan QR. Structural mechanism of ligand activation in human GABA(B) receptor. Nature 2013; 504(7479): 254-9.
56. Furness JB, Callaghan BP, Rivera LR, Cho HJ. The enteric nervous system and gastrointestinal innervation: integrated local and central control. Adv Exp Med Biol 2014; 817: 39-71.
57. Furness JB, Kunze WAA, Bertrand PP, Clerc N, Bornstein JC. Intrinsic primary afferent neurons of the intestine. Prog Neurobiol 1998; 54: 1-18.
58. Hansen MB. Neurohumoral control of gastrointestinal motility. Physiol Res 2003; 52: 1-30.
59. Goaillard JM, Marder E. Exciting guts with GABA. Nat Neurosci 2003; 6(11): 1121-2.
60. Modi JP, Prentice H, Wu JY. Regulation of GABA Neurotransmission by Glutamic Acid Decarboxylase (GAD). Curr Pharm Design 2015; 21(34): 4939-42.
61. Taniyama, K, Kusunoki M, Saito N, Tanaka C. Release of gammaaminobutyric acid from cat colon. Science 1982; 217: 1038-40.
62. Fletcher EL, Clark MJ, Furness JB. Neuronal and glial localization of GABA transporter immunoreactivity in the myenteric plexus. Cell Tissue Res 2002; 308(3): 339-46.
63. Auteri M, Zizzo MG, Serio R. GABA and GABA receptors in the gastrointestinal tract: from motility to inflammation. Pharmacol Res 2015; 93: 11-21.
64. Park K B, Ji GE, Park MS, Oh SH. Expression of rice glutamate decarboxylase in Bifidobacterium longum enhances gammaaminobutyric acid production. Biotechnol Lett 2005; 27: 1681-4.
65. Nakajima K, Tooyama I, Kuriyama K, Kimura H. Immunohistochemical demonstration of GABAB receptors in the rat gastrointestinal tract. Neurochem Res 1996; 21: 211-5.
66. Zeiter DK, Li X, Broussard DL. Identification of the GABAA receptor alpha-subunit mRNA in rat intestine. Brain Res Mol Brain Res 1996; 39: 241-4.
67. Poulter MO, Singhal R, Brown LA, Krantis A. GABA(A) receptor subunit messenger RNA expression in the enteric nervous system of the rat: implications for functional diversity of enteric GABA(A) receptors. Neuroscience 1999; 93: 1159-65.
68. Seifi M, Brown JF, Mills J, et al. Molecular and functional diversity of GABA-A receptors in the enteric nervous system of the mouse colon. J Neurosci 2014; 34(31): 10361-78.
69. Tonini M, De Petris G, Onori L, Manzo L, Rizzi CA, Crema A. The role of GABAA receptor function in peristaltic activity of the guinea-pig ileum: a comparative study with bicuculline, SR 95531 and picrotoxinin. Br J Pharmacol 1989; 97: 556-62.
70. Tonini M, Crema A, Frigo GM, et al. An in vitro study of the relationship between GABA receptor function and propulsive motility in the distal colon of the rabbit. Br J Pharmacol 1989; 98: 1109-18.
71. Roberts DJ, Hasler WL, Owyang C. GABA mediation of the dual effects of somatostatin on guinea pig ileal myenteric cholinergic transmission. Am J Physiol 1993; 264: 953-60.
72. Minocha A, Galligan JJ. Excitatory and inhibitory responses mediated by GABAA and GABAB receptors in guinea pig distal colon. Eur J Pharmacol 1993; 230: 187-93.
73. Bayer S, Jellali A, Crenner F, Aunis D, Angel F. Functional evidence for a role of GABA receptors in modulating nerve activities of circular smooth muscle from rat colon in vitro. Life Sci 2003; 72: 1481-93.
74. Taniyama K, Hashimoto S, Hanada S, Tanaka C. Benzodiazepines and barbiturate potentiate the pre- and postsynaptic gammaaminobutyric acid (GABA)A receptor-mediated response in the enteric nervous system of guinea pig small intestine. J Pharmacol Exp Ther 1988; 245(1): 250-6.
75. Liu S, Ji T, Ren W, Qu MH, Zhu JX, Wood JD. Role of Na-K-2Cl symporter in GABA-evoked excitation in rat enteric neurons. FASEB J 2013; 27: 1160.5
76. Zizzo MG, Mule F, Serio R. Functional evidence for GABA as modulator of the contractility of the longitudinal muscle in mouse duodenum: role of GABA(A) and GABA(C) receptors. Neuropharmacology 2007; 52(8): 1685-90.
77. Hyland NP, Cryan JF. A gut feeling about GABA: focus on GABAB receptors. Frontiers in pharmacology 2010; 1: 124.
78. Cherubini E, North RA. Inhibition of calcium spikes and transmitter release by gamma-aminobutyric acid in the guinea-pig myenteric plexus. Br J Pharmacol 1984; 82: 101-5.
79. Marcoli M, Scarrone S, Maura G, Bonanno G, Raiteri M. A subtype of the gamma-aminobutyric acid(B) receptor regulates cholinergic twitch response in the guinea pig ileum. J Pharmacol Exp Ther 2000; 293: 42-7.
80. Krantis A, Tufts K, Nichols K, Morris GP. [3H]GABA uptake and GABA localization in mucosal endocrine cells of the rat stomach and colon. J Auton Nerv Syst 1994; 47(3): 225-32.
81. Davanger S, Hjelle OP, Babaie E et al. Colocalization of gammaaminobutyrate and gastrin in the rat antrum: an immunocytochemical and in situ hybridization study. Gastroenterology 1994; 107(1):137-48.
82. Calver AR, Medhurst AD, Robbins MJ, et al. The expression of GABA(B1) and GABA(B2) receptor subunits in the CNS differs from that in peripheral tissues. Neuroscience 2000; 100(1): 155-70.
83. Torashima Y, Uezono Y, Kanaide M, et al. Presence of GABA(B) receptors forming heterodimers with GABA(B1) and GABA(B2) subunits in human lower esophageal sphincter. J Pharmacol Sci 2009; 111(3): 253-9.
84. Sarkar S, Thompson DG, Woolf CJ, Hobson AR, Millane T, Aziz Q. Patients with chest pain and occult gastroesophageal reflux demonstrate visceral pain hypersensitivity which may be partially responsive to acid suppression Am J Gastroenterol 2004; 99(10):1998-2006.
85. Srinath AI, Walter C, Newara MC, Szigethy EM. Pain management in patients with inflammatory bowel disease: insights for the clinician. Therap Adv Gastroenterol 2012; 5(5): 339-57.
86. Fukudo S. Stress and visceral pain: focusing on irritable bowel syndrome. Pain 2013; 154 (Suppl 1): S63-70.
87. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 177-93.
88. Sengupta JN. Visceral pain: the neurophysiological mechanism. Handb Exp Pharmacol 2009; 194: 31-74.
89. Page AJ, Blackshaw LA. GABAB receptors inhibit mechanosensitivity of primary afferent endings. J Neurosci 1999; 19: 8597-602.
90. Riley RC, Trafton JA, Chi SI, Basbaum AL. Presynaptic regulation of spinal cord tachykinin signaling via GABAB but not GABAA receptor activation. Neuroscience 2001; 103: 725-37.
91. Brusberg M, Ravnefjord A, Martinsson R, Larsson H, Martinez V, Lindstrom E. The GABA(B) receptor agonist, baclofen, and the positive allosteric modulator, CGP7930, inhibit visceral painrelated responses to colorectal distension in rats. Neuropharmacology 2009; 56: 362-7.
92. Lindstrom E, Brusberg M, Ravnefjord A, et al. Oral baclofen reduces visceral pain-related pseudo-affective responses to colorectal distension in rats: relation between plasma exposure and efficacy. Scand J Gastroenterol 2011; 46: 652-62.
93. Liu LS, Shenoy M, Pasricha PJ. The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia. Neurogastroenterol Motil 2011; 23(356-61): e160-1.
94. Hara K, Saito Y, Kirihara Y, Yamada Y, Sakura, S, Kosaka Y. The interaction of antinociceptive effects of morphine and GABA receptor agonists within the rat spinal cord. Anesth Analg 1999; 89:422-7.
95. Sengupta JN, Medda BK, Shaker R. Effect of GABAB receptor agonist on distension-sensitive pelvic nerve afferent fibers innervating rat colon. Am J Physiol Gastrointest Liver Physiol 2002; 283: 1343-51.
96. Yamamoto T, Walsh TL. Effects of intrathecal strychnine and bicuculline on nerve compression-induced thermal hyperalgesia and selective antagonism by MK-801. Pain 1993; 54: 79-84.
97. Lin Q, Peng YB, Willis WD. Inhibition of primate spinothalamic tract neurons by spinal glycine and GABA is reduced during central sensitization. J Neurophysiol 1996; 76: 1005-14.
98. Ibuki T, Hama AT, Wang XT, Pappas GD, Sagen J. Loss of GABA immunoreactivity in the spinal dorsal horn of rats with peripheral nerve injury and promotion or recovery by adrenal medullary grafts. Neuroscience 1997; 76: 845-58.
99. Page AJ, O’Donnell TA, Blackshaw LA. Inhibition of mechanosensitivity in visceral primary afferents by GABAB receptors involves calcium and potassium channels. Neuroscience 2006; 137(2): 627-36.
100. Huang D, Huang S, Peers C, Du X, Zhang H, Gamper N. GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms. Biochem Biophys Res Commun 2015; 465(2): 188-93.
101. Marvizon JC, Grady EF, Stefani E, Bunnett NW, Mayer EA. Substance P release in the dorsal horn assessed by receptor internalization:NMDA receptors counteract a tonic inhibition by GABAB receptors. Eur J Neurosci 1999; 11(2): 417-26.
102. Andrews PL, Sanger GJ. Abdominal vagal afferent neurones: an important target for the treatment of gastrointestinal dysfunction. Curr Opin Pharmacol 2002; 2(6): 650-6.
103. Occhipinti K, Smith JW. Irritable bowel syndrome: a review and update. Clin Colon Rectal Surg 2012; 25(1): 46-52.
104. Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26(Suppl 3): 119-21.
105. Tache Y, Kiank C, Stengel A. A role for corticotropin-releasing factor in functional gastrointestinal disorders. Curr Gastroenterol Rep 2009; 11(4): 270-7.
106. Million M, Maillot C, Adelson DA, et al. Peripheral injection of sauvagine prevents repeated colorectal distension-induced visceral pain in female rats. Peptides 2005; 26: 1188-95.
107. Nozu T, Kudaira M. Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans. J Gastroenterol 2006; 41: 740-4.
108. Chen C, Han CH, Sweeney M, Cowles VE. Pharmacokinetics, efficacy, and tolerability of a once-daily gastroretentive dosage form of gabapentin for the treatment of postherpetic neuralgia. J Pharm Sci 2013; 102(4): 1155-64.
109. Lu Y, Westlund KN. Gabapentin attenuates nociceptive behaviors in an acute arthritis model in rats. J Pharmacol Exp Ther 1999; 290:214-9.
110. Lee KJ, Kim JH, Cho SW. Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoeapredominant irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 981-8.
111. O’Mahony SM, Coelho AM, Fitzgerald P, et al. The effects of gabapentin in two animal models of co-morbid anxiety and visceral hypersensitivity. Eur J Pharmacol 2011; 667: 169-74.
112. Ravnefjord A, Brusberg M, Larsson H, Lindstrom E, Martinez V. Effects of pregabalin on visceral pain responses and colonic compliance in rats. Br J Pharmacol 2008; 155(3): 407-16.
113. Diop L, Raymond F, Fargeau H, Petoux F, Chovet M, Doherty AM. Pregabalin (CI-1008) inhibits the trinitrobenzene sulfonic acid-induced chronic colonic allodynia in the rat. J Pharmacol Exp Ther 2002; 302(3): 1013-22.
114. Million M, Wang L, Adelson DW, Roman F, Diop L, Tache Y. Pregabalin decreases visceral pain and prevents spinal neuronal activation in rats. Gut 2007; 56: 1482-4.
115. Houghton LA, Fell C, Whorwell PJ, Jones I, Sudworth DP, Gale JD. Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut 2007; 56(9): 1218-25.
116. Iturrino J, Camilleri M, Busciglio I, Burton D, Zinsmeister AR. Effect of the α2δ ligand, pregabalin, on colonic sensory and motor functions in healthy adults. Am J Physiol Gastrointest Liver Physiol 2011; 301(2): 377-84.
117. Iturrino J, Camilleri M, Busciglio I, Burton D, Zinsmeister AR. Pilot trial: pregabalin on colonic sensorimotor functions in irritable bowel syndrome. Dig Liver Dis 2014; 46(2): 113-8.
118. Offord J, Isom LL. Drugging the undruggable: gabapentin, pregabalin and calcium channel α2δ subunit. Crit Rev Biochem Mol Biol 2015, 51(4): 246-56.
119. Young RR, Delwaide PJ. Drug therapy: spasticity. N Engl J Med 1981; 304: 96-9.
120. Sandyk R, Gillman MA. Baclofen-induced memory impairment. Clin Neuropharmacol 1985; 8: 294-5.
121. Barber RP, Vaughn JE, Saito K, McLaughlin BJ, Roberts E. GABAergic terminals are presynaptic to primary afferent terminals in the substantia gelatinosa of the rat spinal cord. Brain Res 1978; 141: 35-55.
122. Craft RM, Henley SR, Haaseth RC, Hruby VJ, Porreca F. Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. J Pharmacol Exp Ther 1995; 275: 1535-42.
123. Reichert JA, Daughters RS, Rivard R, Simone DA. Peripheral and preemptive opioid antinociception in a mouse visceral pain model. Pain 2001; 89: 221-7.
124. Randich A, Gebhart GF. Vagal afferent modulation of nociception. Brain Res Brain Res Rev 1992; 17(2): 77-99.
125. Vaughan CW, Ingram SL, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 1997; 390(6660): 611-4.
126. Santos J, Perdue MH. Stress and neuroimmune regulation of gut mucosal function. Gut 2000; 47(Suppl4): 49-51.
127. Kraneveld AD, Rijnierse A, Nijkamp FP, Garssen J. Neuroimmune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol 2008; 585(2-3): 361-74.
128. Jin Z, Mendu SK, Birnir B. GABA is an effective immunomodulatory molecule. Amino Acids 2013; 45(1): 87-94.
129. Bjurstom H, Wang J, Ericsson I, et al. GABA, a natural immunomodulator of T lymphocytes. J Neuroimmunol 2008; 205(1-2): 44-50.
130. Bhat R, Axtell R, Mitra A, et al. Inhibitory role for GABA in autoimmune inflammation. Proc Natl Acad Sci USA 2010; 107(6):2580-5.
131. Tian J, Yong J, Dang H, Kaufman DL. Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 2011; 44(6): 465-70.
132. MacNaughton WK, Pineau BC, Krantis A. gamma-Aminobutyric acid stimulates electrolyte transport in the guinea pig ileum in vitro. Gastroenterology 1996; 110: 498-507.
133. Li Y, Xiang YY, Lu WY, Liu C, Li J. A novel role of intestine epithelial GABAergic signaling in regulating intestinal fluid secretion. Am J Physiol Gastrointest Liver Physiol 2012; 303(4): 453-60.
134. Vlainić J, Šuran J, Vlainić T, Vukorep AL. Probiotics as an adjuvant therapy in major depressive disorder. Curr Neuropharmacol 2016. In press.
135. Shale M, Schiering C, Powrie F. CD4(+) T-cell subsets in intestinal inflammation. Immunol Rev 2013; 252(1): 164-82.
136. Janeway CA Jr, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 5th edition. New York:Garland Science, 2001.
137. Tian J, Dang HN, Yong J, Chui WS, Dizon MP, Yaw CK, Kaufman DL. Oral treatment with γ-aminobutyric acid improves glucose tolerance and insulin sensitivity by inhibiting inflammation in high fat diet-fed mice. PLoS One 2011; 6(9): e25338.
138. Soltani N, Qiu H, Aleksic M, et al. GABA exerts protective and regenerative effects on islet beta cells and reverses diabetes. Proc Natl Acad Sci USA 2011; 108: 11692-7.
139. Kalashnikov SV, Kalashnikova EA, Kokarovtseva SN. Immunomodulating effects of tofizopam (Grandaxin) and diazepam in vitro. Mediators Inflamm 2002; 11: 53-59.
140. Mawdsley JE, Rampton DS. Psychological stress in IBD: new insights into pathogenic and therapeutic implications. Gut 2005; 54(10): 1481-91.
141. Agelaki S, Tsatsanis C, Gravanis A, Margioris AN. Corticotropinreleasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 2002; 70: 6068-74.
142. O’Connor TM, O’Connell J, O’Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004; 201(2): 167-80.
143. Szabo S, Tolstanova G. New molecules as drug candidates for the treatment of upper and lower GI tract ulcers. Curr Pharm Des 2015; 21(21): 2993-3001.